PAI
SAGE

Palo Alto Investors’s Sage Therapeutics SAGE Stock Holding History

Palo Alto Investors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,010,833
Closed -$7.3M – 46
2024
Q3 		$7.3M Hold
1,010,833
– – 0.95% 21
2024
Q2 		$11M Buy
1,010,833
+5,057
+0.5% +$64.8K 1.27% 15
2024
Q1 		$18.8M Buy
1,005,776
+14,251
+1% +$329K 2.13% 13
2023
Q4 		$21.5M Sell
991,525
-14,251
-1% -$282K 1.94% 12
2023
Q3 		$20.7M Buy
1,005,776
+146,259
+17% +$4.22M 1.96% 10
2023
Q2 		$40.4M Hold
859,517
– – 3.27% 10
2023
Q1 		$36.1M Buy
859,517
+3,000
+0.4% +$129K 2.99% 10
2022
Q4 		$32.7M Buy
856,517
+5,108
+0.6% +$195K 2.79% 10
2022
Q3 		$33.3M Hold
851,409
– – 2.64% 10
2022
Q2 		$27.5M Sell
851,409
-310
-0% -$10.4K 2.4% 10
2022
Q1 		$28.2M Buy
851,719
+69,989
+9% +$2.63M 2.18% 12
2021
Q4 		$33.3M Buy
781,730
+163,800
+27% +$6.86M 2.13% 15
2021
Q3 		$27.4M Buy
617,930
+17,430
+3% +$799K 1.65% 16
2021
Q2 		$34.1M Hold
600,500
– – 1.88% 15
2021
Q1 		$44.9M Buy
600,500
+10,300
+2% +$844K 2.56% 14
2020
Q4 		$51.1M Hold
590,200
– – 2.68% 14
2020
Q3 		$36.1M Buy
590,200
+15,000
+3% +$760K 1.98% 14
2020
Q2 		$23.9M Sell
575,200
-11,474
-2% -$416K 1.44% 17
2020
Q1 		$16.8M Sell
586,674
-66,920
-10% -$3.88M 1.41% 17
2019
Q4 		$47.2M Sell
653,594
-27,300
-4% -$3.36M 2.6% 16
2019
Q3 		$95.5M Sell
680,894
-114,137
-14% -$19.1M 6.36% 6
2019
Q2 		$146M Sell
795,031
-62,650
-7% -$10.7M 7.08% 4
2019
Q1 		$136M Buy
857,681
+6,704
+0.8% +$971K 5.69% 7
2018
Q4 		$81.5M Buy
850,977
+10,605
+1% +$1.21M 4.34% 9
2018
Q3 		$119M Buy
840,372
+7,836
+0.9% +$1.21M 4.8% 8
2018
Q2 		$130M Buy
832,536
+14,205
+2% +$2.23M 5.21% 7
2018
Q1 		$132M Buy
818,331
+7,525
+0.9% +$1.28M 5.64% 6
2017
Q4 		$134M Buy
810,806
+23,555
+3% +$2.28M 5.75% 7
2017
Q3 		$49M Sell
787,251
-245,774
-24% -$19.3M 2.07% 14
2017
Q2 		$82.3M Sell
1,033,025
-68,926
-6% -$4.98M 3.84% 8
2017
Q1 		$78.3M Buy
1,101,951
+92,021
+9% +$5.39M 3.7% 10
2016
Q4 		$51.6M Buy
1,009,930
+107,879
+12% +$5.08M 2.94% 11
2016
Q3 		$41.5M Buy
902,051
+484,173
+116% +$19.7M 2.41% 15
2016
Q2 		$12.6M Buy
+417,878
New +$13.9M 0.95% 26

Other funds holding SAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Palo Alto Investors's SAGE Position: Q4 2024 in Review

Palo Alto Investors sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 1,010,833 shares — an estimated $7.3M sold.

Palo Alto Investors first reported a position in SAGE in Q2 2016 and held it in 34 quarters. The position peaked at $146M in Q2 2019. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

  • Palo Alto Investors reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Palo Alto Investors sold 1,010,833 Sage Therapeutics shares in Q4 2024, an estimated $7.3M.
  • Palo Alto Investors first reported a position in Sage Therapeutics in Q2 2016 and held it in 34 quarters.
  • Palo Alto Investors's Sage Therapeutics position peaked at $146M in Q2 2019.
  • 177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Palo Alto Investors's 13F filing for Q4 2024, filed 14 Feb 2025.